Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metrifonate for Alzheimer's disease.

J M López-Arrieta1, L Schneider

  • 1Consejería de Sanidad. Comunidad de Madrid, Hospital General Universitario Gregorio Marañón - Cantoblanco, Carretera de Colmenar km 14.500, Madrid, SPAIN, 28049. jess.arrieta@nacom.es

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary

Metrifonate showed cognitive and functional improvements in Alzheimer's disease (AD) patients, but trials were halted due to rare neuromuscular side effects. Further development was discontinued.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance and nutrient composition of black soldier fly larvae fed diets with various protein concentrations throughout the life cycle.

Animal : an international journal of animal bioscience·2025
Same author

Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France.

The Journal of antimicrobial chemotherapy·2025
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.

The Journal of antimicrobial chemotherapy·2025
Same author

Knowledge, attitudes and practices on prevention and control of high-consequence infectious diseases and critical care among intensive care personnel in Rwanda: a cross-sectional survey.

Infection prevention in practice·2024
Same author

Extrahepatic Bile Duct Organoids as a Model to Study Ischemia/Reperfusion Injury During Liver Transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2024

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Metrifonate, a cholinesterase inhibitor, was investigated for Alzheimer's disease (AD) treatment.
  • Initial use for schistosomiasis showed potential for enhancing central nervous system cholinergic neurotransmission.

Purpose of the Study:

  • To evaluate metrifonate's efficacy in improving cognition, global impression, and functional activity in AD patients.
  • To assess the safety and tolerability of metrifonate in AD patients.

Main Methods:

  • Systematic review of randomized, double-blind, placebo-controlled trials of metrifonate in AD patients.
  • Data extraction and pooling from published and non-published clinical trial data.

Main Results:

  • Metrifonate demonstrated significant cognitive improvement (MMSE, ADAS-Cog) and global impression enhancement compared to placebo.

Related Experiment Videos

  • Improvements were also observed in activities of daily living, though dependent on sample size and instrument used.
  • Adverse events like abdominal pain and nausea were mostly mild, but rare cases of neuromuscular dysfunction and respiratory failure led to trial discontinuation.

    • Conclusions:

    • Metrifonate showed potential for clinical response in cognition, global improvement, and daily living activities in mild to moderate AD.
    • While generally well-tolerated, rare severe adverse events led to the withdrawal of metrifonate from further development.